目的 探讨培美曲塞联合卡铂与顺铂对复发性卵巢上皮癌患者的疗效及安全性。方法 回顾性选择濮阳市油田总医院2012年1月-2015年12月收治的53例复发性卵巢上皮癌患者，根据化疗方法的不同分为A组及B组，A组26例，采用培美曲塞联合顺铂治疗，B组27例，采用培美曲塞联合卡铂治疗，对比两组的临床疗效、无进展生存期及不良反应。结果 A组治疗有效率为34.6%，B组为40.7%，两组有效率对比无统计学意义。A组平均无进展生存期为（9.1±1.9）个月，B组为（9.7±1.8）个月，组间对比无统计学意义。A、B两组的Ⅲ~Ⅳ血液学毒性、乏力、Ⅲ~Ⅳ消化道反应对比无统计学意义；而B组的Ⅲ~Ⅳ周围神经病变、Ⅲ~Ⅳ脱发、发热发生率明显低于A组，差异有统计学意义（P<0.05）。结论 培美曲塞联合卡铂与培美曲塞联合顺铂对复发性卵巢上皮癌的效果相当，但培美曲塞联合卡铂的安全性较高。

Objective To investigate the efficacy and safety of pemetrexed combined with carboplatin and cisplatin in patients with recurrent ovarian epithelial cancer.Methods 53 cases with recurrent ovarian epithelial cancer from Jan.2012 to Dec.2015 in our hospital were retrospective selection,who were divided into the group A (26 cases) and group B (27 cases),group A were given pemetrexed combination with cisplatin,group B were given pemetrexed combination with carboplatin,the clinical efficacy,progression-free survival and adverse events of two groups were compared.Results The clinical efficacy of group A was 34.6%,the group B was 40.7%,which in two groups had no significant difference.The progression-free survival of group A was (9.1 ±1.9) months,which in the group B was (9.7 ±1.8) months.The Ⅲ-Ⅳ hematological toxicity,weak,Ⅲ-Ⅳ digestive tract reaction of two groups had no significant difference.The Ⅲ-Ⅳ peripheral neuropathy,Ⅲ-Ⅳ hair loss,fever of group B were lower than group A (P< 0.05).Conclusion Pemetrexed combined with carboplatin and pemetrexed combined with cisplatin was equally effective in recurrent ovarian epithelial cancer,while pemetrexed combined with carboplatin was safer.